Linagliptin and pioglitazone combination therapy versus monotherapy with linagliptin or pioglitazone: A randomised, double-blind, parallel-group, multinational clinical trial
| Autor: | Maximiliano di Domenico, Michael A. Nauck, Sanjay Patel, Hans-Juergen Woerle, Maureen Kobe, Robert Toorawa |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Time Factors Combination therapy Endocrinology Diabetes and Metabolism Administration Oral 030209 endocrinology & metabolism Linagliptin 030204 cardiovascular system & hematology Double blind 03 medical and health sciences 0302 clinical medicine Double-Blind Method Diabetes mellitus Internal medicine Lifestyle intervention Internal Medicine medicine Humans Hypoglycemic Agents Aged Glycated Hemoglobin Dipeptidyl-Peptidase IV Inhibitors Pioglitazone business.industry Middle Aged medicine.disease Hypoglycemia United States Clinical trial Europe Drug Combinations Treatment Outcome Diabetes Mellitus Type 2 Female Thiazolidinediones Cardiology and Cardiovascular Medicine business Biomarkers medicine.drug Tablets |
| Zdroj: | Diabetesvascular disease research. 13(4) |
| ISSN: | 1752-8984 |
| Popis: | Linagliptin plus pioglitazone single-pill combinations were evaluated. Patients ( n = 936) with insufficient glycaemic control, despite lifestyle interventions, were randomised for 30 weeks to either monotherapy with linagliptin 5 mg; pioglitazone 15, 30 or 45 mg; or single-pill combination with linagliptin 5 mg plus pioglitazone 15, 30 or 45 mg. An extension (⩽54 weeks) planned to evaluate linagliptin plus pioglitazone 30 or 45 mg single-pill combinations was not completed due to a protocol amendment. Adjusted mean (95% confidence interval) differences in HbA1c change from baseline at week 30 for linagliptin plus pioglitazone 15, 30 and 45 mg were −0.17% (−0.41, 0.07), −0.37% (−0.60, −0.14) and −0.41% (−0.64, −0.18) versus pioglitazone monotherapies, respectively, and −0.44% (−0.67, −0.20), −0.68% (−0.91, −0.44) and −0.89% (−1.12, −0.66) versus linagliptin monotherapy, respectively. Single-pill combinations were generally well tolerated. Hypoglycaemia frequency was ⩽1.5% per group. Linagliptin plus pioglitazone combinations were efficacious, with safety profiles comparable to the individual monotherapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|